Reference Detail

Ref Type

Journal Article

PMID

(39626159)

Authors

Simhadri S, Carrick JN, Murphy S, Kothari OA, Al-Hraishami H, Kulkarni A, Jalloul N, Stefanik K, Bandari M, Chettur K, Yao M, Ginjala V, Groisberg R, Hochster H, Mehnert J, Riedlinger G, Khiabanian H, Verzi MP, Tong K, Ganesan S

Title

Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer.

Journal	Vol	Issue	Date	Pages	Journal Short Title
JCO precision oncology	8		2024 Dec	e2300260	JCO Precis Oncol

URL

Abstract Text

Combined BRAF, MEK, and EGFR inhibition can induce clinical responses in BRAF-V600E-mutant colon cancer, but rapid resistance often occurs.We use serial monitoring of circulating tumor DNA cell-free plasma DNA (cfDNA) in a patient case study in addition to organoids derived from mouse models of BRAF-V600E-mutant intestinal cancer, which emulated the patient's mutational profile to assess drug treatment efficacy.We demonstrate dynamic evolution of resistance to combined EGFR/BRAF/MEK inhibition in a pediatric patient with metastatic BRAF-V600E-mutant, mismatch repair-stable colon cancer. Initial resistance to targeted therapy was associated with development of MET amplification. Sequential treatment with chemotherapy and targeted therapy resulted in clearing of the resistant MET-amplified clone. Rechallenge with combined BRAF/EGFR inhibition resulted in clinical and radiographic response, demonstrating these treatments may be non-cross-resistant. Tumor organoids were used to model clinical findings and demonstrated effectiveness of combined targeted therapy and chemotherapy.These findings suggest rational strategies for combining sequential chemotherapy and BRAF-/EGFR-directed therapy in BRAF-V600E-mutant colon cancer to prevent resistance and improve outcome. The data demonstrate rapid clonal dynamics in response to effective therapies in BRAF-V600E-mutant colon cancer that can be monitored by serial cfDNA analysis. Moreover, in mismatch repair-proficient BRAF-V600E-mutant colon cancers, combined EGFR and BRAF/MEK therapy is not cross-resistant with standard chemotherapy, suggesting new rational combination treatment strategies.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF V600E	colon cancer	predicted - sensitive	Dabrafenib + Panitumumab + Trametinib	Case Reports/Case Series	Actionable	In a clinical study, treatment with the combination of Vectibix (panitumumab), Tafinlar (dabrafenib), and Mekinist (trametinib) resulted in a clinical response in a pediatric patient with colon cancer harboring BRAF V600E, as well as TP53 G245S, SMAD4 S504R, and PTEN loss, with decreased liver metastases and reduction in CA-19-9 and BRAF V600E VAF levels in the cell free DNA (PMID: 39626159; NCT02688517).	39626159
BRAF V600E	colon cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, mouse colon cancer organoids harboring BRAF V600E were resistant to Zelboraf (vemurafenib) in culture (PMID: 39626159).	39626159
BRAF V600E	colon cancer	sensitive	Erlotinib + Fluorouracil + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Adrucil (fluorouracil) to treatment with the combination of Tarceva (erlotinib) and Zelboraf (vemurafenib) resulted in greater inhibition of viability of mouse colon cancer organoids harboring BRAF V600E in culture compared to Adrucil (fluorouracil) or the doublet combination therapy (PMID: 39626159).	39626159
BRAF V600E	colon cancer	sensitive	Erlotinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tarceva (erlotinib) to treatment with Zelboraf (vemurafenib) inhibited viability of mouse colon cancer organoids harboring BRAF V600E in culture (PMID: 39626159).	39626159